Compugen Ltd. announced on February 26, 2025, the results of a joint research collaboration with Ultima Genomics, integrating Compugen's AI/ML-powered Unigen™ platform with Ultima's UG 100 single-cell sequencing technology. This collaboration aims to uncover new insights into gene structure for immuno-oncology.
The research involved developing algorithms to study gene splicing at single-cell resolution and applying them to analyze patient tumor samples, revealing potential new regulatory mechanisms. These findings were presented at the AGBT 2025 conference.
Compugen plans to further leverage Ultima's technology to develop proprietary single-cell atlases, which are expected to accelerate the discovery of new immunotherapies. This enhancement to the Unigen™ platform reinforces Compugen's commitment to innovation in drug target discovery.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.